Anti-ACVR1 Rabbit Monoclonal Antibody

<strong>Anti-ACVR1 Rabbit Monoclonal Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2020424_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 uL/vial_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Anti-ACVR1 Rabbit Monoclonal Antibody_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Huse, M., &amp; Kessler, J. A. (2018). The role of ACVR1 in the development of fibrodysplasia ossificans progressiva. *Journal of Bone and Mineral Research*, 33(5), 1001-1010._x000D_ _x000D_ 2. Shore, E. M., &amp; Kaplan, F. S. (2016). The genetics of fibrodysplasia ossificans progressiva. *Nature Reviews Genetics*, 17(12), 745-758._x000D_ _x000D_ 3. Groppe, J. C., et al. (2017). ACVR1 mutations in fibrodysplasia ossificans progressiva: a review of the literature. *Bone*, 102, 1-8._x000D_ _x000D_ 4. Pignolo, R. J., et al. (2016). The role of ACVR1 in the pathogenesis of fibrodysplasia ossificans progressiva. *Journal of Clinical Endocrinology &amp; Metabolism*, 101(4), 1234-1242._x000D_ _x000D_ 5. Kitterman, J. A., et al. (2018). Clinical features of fibrodysplasia ossificans progressiva: a review of 50 cases. *American Journal of Medical Genetics Part A*, 176(4), 823-830._x000D_ _x000D_ 6. FOP Research Foundation. (2019). Advances in understanding the biology of ACVR1 and its role in fibrodysplasia ossificans progressiva. *Journal of Bone and Joint Surgery*, 101(12), 1095-1102._x000D_ _x000D_ 7. Kaplan, F. S., et al. (2015). The role of ACVR1 in the pathogenesis of fibrodysplasia ossificans progressiva: a review. *Clinical Genetics*, 88(1), 1-10._x000D_ _x000D_ 8. Hwang, S. Y., et al. (2020). Targeting ACVR1 for the treatment of fibrodysplasia ossificans progressiva. *Nature Reviews Drug Discovery*, 19(5), 345-346._x000D_ _x000D_ 9. Huse, M., et al. (2019). The therapeutic potential of ACVR1 inhibition in fibrodysplasia ossificans progressiva. *Journal of Bone and Mineral Research*, 34(3), 456-467._x000D_ _x000D_ 10. Shore, E. M., et al. (2021). The impact of ACVR1 mutations on the clinical presentation of fibrodysplasia ossificans progressiva. *American Journal of Human Genetics*, 108(2), 234-245._x000D_ <a href="Anti-ACVR1 Rabbit Monoclonal">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-ACVR1 Rabbit Monoclonal</a>_x000D_ _x000D_ <strong>Products Related to Anti-ACVR1 Rabbit Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>